Korea’s P-CAB Market Enters New Phase as Japanese Drugmakers Join Race

Takeda logo. (Source: Takeda official website) South Korea's market for treatments for gastroesophageal reflux disease is rapidly shifting from proton pump inhibitors (PPIs) to potassium-competitive acid blockers (P-CABs), as a growing market draws new competitors. P-CAB drugs can be taken regardless of meals and take effect quickly, with annual prescription sales expected to surpass 400 billion…